Voronoi, Inc.

KOSDAQ:A310210 Stock Report

Market Cap: ₩3.6t

Voronoi Past Earnings Performance

Past criteria checks 0/6

Voronoi's earnings have been declining at an average annual rate of -27.1%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 19% per year.

Key information

-27.09%

Earnings growth rate

-18.79%

EPS growth rate

Biotechs Industry Growth11.70%
Revenue growth rate19.02%
Return on equity-55.09%
Net Margin-673.58%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Analysis Article Apr 25

Voronoi (KOSDAQ:310210) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. Indeed, Voronoi ( KOSDAQ:310210...
Analysis Article Jan 03

Voronoi (KOSDAQ:310210) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Sep 20

Health Check: How Prudently Does Voronoi (KOSDAQ:310210) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article May 28

Is Voronoi (KOSDAQ:310210) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Revenue & Expenses Breakdown

How Voronoi makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A310210 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 267,512-50,60131,54235,430
31 Dec 257,512-42,70628,61031,013
30 Sep 257,490-47,26325,45928,579
30 Jun 253,350-42,89522,35223,459
31 Mar 250-40,15219,29721,619
31 Dec 240-32,61316,08517,894
30 Sep 240-38,87915,16417,322
30 Jun 240-36,06614,62814,815
31 Mar 240-35,04014,01313,484
31 Dec 230-36,84813,81614,464
30 Sep 23589-30,99113,48313,900
30 Jun 237,943-22,87613,11713,862
31 Mar 238,630-22,14312,84313,326
31 Dec 229,768-19,90012,59911,727
30 Sep 2213,845-14,09512,25211,316
30 Jun 2212,167-18,10812,13913,402
31 Mar 2214,419-18,83311,61113,121
31 Dec 2114,784-15,0969,65012,492
30 Sep 2116,095-12,47210,23311,913
31 Dec 206,180-23,18716,26213,412
31 Dec 19301-50,00320,16631,498
31 Dec 18174-9,2183,5187,047
31 Dec 1734-1,8821,687724

Quality Earnings: A310210 is currently unprofitable.

Growing Profit Margin: A310210 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A310210 is unprofitable, and losses have increased over the past 5 years at a rate of 27.1% per year.

Accelerating Growth: Unable to compare A310210's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A310210 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.6%).


Return on Equity

High ROE: A310210 has a negative Return on Equity (-55.09%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/29 17:02
End of Day Share Price 2026/06/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Voronoi, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Heeyoung LeeDaishin Securities Co. Ltd.
Ho-cheol LeeShinhan Investment Corp.
Hyun-soo HaYuanta Securities Korea Co., Ltd.